During a live event, Andrew Kuykendall, MD, discussed management of anemia before and during use of JAK inhibitor for ...
In this episode of Targeted Talks, Aditya Bardia, MD, MPH, FASCO, discusses the recent FDA approval of datopotamab deruxtecan ...
Evan Y. Yu, MD, discusses the safety data from the phase 3 PEACE-3 study of enzalutamide (ENZA) combined with radium-223 ...
On January 7, 2025, the FDA granted priority review to the new drug application for sunvozertinib (DZD9008), an oral EGFR ...
Evan Y. Yu, MD, discusses the key efficacy findings from the PEACE-3 study, which assessed the combination of enzalutamide (ENZA) and radium-223 (Ra-223) in androgen receptor pathway inhibitor ...
The PATHWAY HER2 (4B5) test is now FDA-approved to assess HER2-ultralow status in metastatic breast cancer, expanding its ...
During a live event, Kathryn E. Beckermann, MD, PhD, discussed the treatment of RCC with insights from a recent trial on ...
A phase 1 study of a personalized cancer vaccine demonstrated antitumor immunity in all treated patients with resected renal ...
Andrea Roman, PharmD, BCOP, US Oncology Network and McKesson, discussed the integration of clinical pharmacists into ...
During a Case-Based Roundtable® event, Nakhle Saba, MD, and participants discussed the data supporting the 2 newer BTK ...
During a Case-Based Roundtable event, Laura Huppert, MD, discussed data and considerations around using T-DXd in breast ...
Marwan G. Fakih, MD, discussed the implications of the findings from the phase 2 study for patients with microsatellite ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback